公司概述
P3 Health Partners Inc. operates as a patient-centered and physician-led population health management entity that delivers superior care services across the United States through its network of clinics and wellness centers. The company functions within the Healthcare sector, specifically the Medical Care Facilities industry, positioning it to capitalize on the ongoing demand for accessible outpatient medical services. Currently, the enterprise holds a market capitalization of $597.32M and generates annual revenue of $1.46B, though specific employee count data is not available in the provided records. These valuation and revenue figures indicate that the company has established a significant operational footprint, reflecting a substantial scale in the competitive landscape of US-based medical care facilities.
财务健康
The company reported a trailing twelve-month revenue of $1.46B alongside a net income of -$147,948,000 and an EBITDA of -$186,138,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operational expenses and losses heavily outweigh gross earnings, resulting in an overall loss for the period. Despite the negative earnings, the firm generated free cash flow of $16.28M, which provides a degree of financial flexibility by indicating that operational cash generation is currently sufficient to cover capital expenditures without immediate reliance on external financing. The gross margin stands at -4.1%, the operating margin at -40.0%, and the profit margin at -10.1%; these negative figures indicate that for every dollar of sales, the company incurs costs exceeding revenue at the gross and operating levels, while the negative profit margin confirms that the bottom line is deeply impacted by these structural losses. On the balance sheet, the company holds $25.01M in cash against $287.28M in debt, a disparity that suggests a highly leveraged position where liabilities significantly exceed liquid assets. The debt-to-equity ratio is listed as N/A, which prevents a standard leverage assessment but the cash-to-debt ratio implies a reliance on equity financing or retained earnings to service the debt load. Liquidity is constrained as evidenced by a current ratio of 0.24, indicating that current assets are less than one-quarter of current liabilities, which poses a challenge for meeting short-term obligations. Return on Equity is reported at -6952.6% and return on assets at -23.5%, metrics that reveal management effectiveness is currently negated by heavy losses, eroding shareholder value and asset utility on a per-dollar basis.
估值评估
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed at -14.00; the negative forward multiple implies that the market prices in continued losses or expects a future earnings trajectory that has not yet materialized in the trailing period. The price-to-book ratio is -0.06, indicating that the market values the company at a fraction of its book value, a situation often seen in distressed or loss-making enterprises where assets may be undervalued on the books or liabilities are substantial. Alternative valuation metrics further illustrate this pricing dynamic, with a price-to-sales ratio of 0.41 and an EV/EBITDA of -1.54, suggesting the market is willing to pay less than half of sales revenue for the company given its negative earnings power. The stock's recent trading range spans from a 52-week low of $1.52 to a high of $11.30, meaning the current price sits significantly below the 52-week high, reflecting recent downward pressure or volatility. The beta is 0.85, which indicates that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market swings compared to a beta of 1.0.
Growth & Income
Revenue growth stands at 3.8% year-over-year, while earnings growth is N/A due to the company's negative earnings position; this divergence implies that top-line growth is not yet translating into profitability, a common characteristic in capital-intensive healthcare expansion phases. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning no dividends are distributed to shareholders as earnings are insufficient to support a payout. Consequently, the company reinvests its limited cash flows and retained earnings back into the business operations to fund growth initiatives rather than distributing income to capital providers. The overall growth and income profile is characterized by modest revenue expansion without current income generation or dividend support, relying on market confidence in future profitability to sustain valuation.